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ABSTRACT  
Aim: Interest in quality of economic analyses is increasing in the field of decision making. The 
Drummond’s checklist is a useful tool. This study aimed to use a weighted version of Drummond’s 
checklist together with a Consensus of experts to derive a new scoring system to improve the 
evaluation of economic analyses of HPV tetravalent vaccine as a case study. 
Methods: Drummond’s checklist is composed of 35 items divided into 3 sections: study design, 
data collection and analysis and interpretation of results. To weight the items, a group of experts 
was asked to attribute a score according to their importance. A bibliographic search of economic 
evaluations of HPV tetravalent vaccine was performed. Two researchers assessed the quality of 
selected studies according to the original and weighted checklist. 
Results: The weighted scores assigned by the Consensus to study design, data collection and 
analysis and interpretation of results were 26, 45 and 48 respectively. Thirteen papers were included 
in the review of economic evaluations of HPV tetravalent vaccine. According to the weighted 
Drummond’s checklist, their median quality score was 74 with a maximum of 119. The highest 
score was reached in study design section. 
Conclusion: According to the weighted Drummond’s checklist, studies were judged of medium 
quality. The main pitfalls were found in issues assigned the highest scores by the Consensus, 
underlying the utility to weight available checklists to improve the estimate of the quality of 
economic analyses. The weighted checklist could be thus proposed as a scoring tool to assess the 
quality.  
 
Keywords [MeSH]: Costs and Cost Analysis, Papillomavirus Vaccines, quality, Health 
Technology Assessment 
 
BACKGROUND 
The introduction of economic evaluation in health started at the end of the 1970s (Weinstein and 
Stason 1977). Since that period, there has been a spreading and growing interest in health economic 
analysis and, at the same time, the emerging need for assuring their methodological and reporting 
quality (Elixhauser 1993; Drummond 1996). As an example, Elixhauser et al. (1993; 1998) 
estimated that the number of economic analyses published in literature increased from 1803 in 
1979-90 to 2222 in 1991-96. 
Economic analyses have been increasingly used by decision-makers in the field of public health in 
order to allocate limited resources (Beutels 2007). The introduction of a new technology causes a 
great mobilisation of resources and, for these reasons, decisions should be supported by high quality 
evidence.  In several European and extra-European countries, decisions about reimbursement and 
price of new drugs are taken considering not only safety, efficacy and effectiveness, but also cost-
effectiveness. In some countries, such as Australia, Canada, Sweden, Netherlands, Ireland, Norway, 
Finland, Belgium, Estonia, Latvia and United Kingdom, this economic analysis is compulsory in 
order to determine the price and reimbursement of new and innovative drugs (Russo 2008). In other 
countries, such as Italy, France, Germany and Greece, the inclusion of pharmacoeconomic analysis 
into price or reimbursement requests is not mandatory (Russo 2008). 
Therefore, the need to control and evaluate the quality of reporting and methods used in 
pharmaeconomic analyses is clearly a fundamental issue for public health decision-makers 
(Jefferson 2002).  
Drummond et al. (1996; 1997) published the guidelines for the evaluation of the quality of 
economic analyses both for authors and reviewers on the basis of a qualitative judgement only; the 
checklist has become one of the most commonly employed in the quality assessment of economic 
evaluations. Moreover, it has been affirmed that the Drummond’s checklist is a feasible tool to 
collect baseline information on the quality of studies, irrespectively of the journals which published 
them (Gerard 2000). Several reports of quality assessment of economic analyses have been 
published (Neumann 2000; Siegel 1996; Gerard 1999; Petrou S 2000). Also, the evaluation of the 
quality of studies is a well-known step in systematic reviews and meta-analyses (Higgins and Green 
2008; Centre for Reviews and Dissemination 2009) which are becoming increasingly important to 
support decision-making. In this context, the need for developing and implementing the use of 
quality assessment tools in the field of economic evaluation is a priority to enable decision-makers 
to understand the reliability and robustness of data (La Torre 2006). Checklists are described as a 
tool for assessing the quality of studies, even though scoring systems are not generally 
recommended. In particular, for economic analysis, available scoring systems were judged to be not 
completely reliable and valid (Thurston 2008). Several experts advocate the use of weighted items 
of checklists for the evaluation of economic analyses (Ungar and Santos 2003; Gonzalez Perez 
2002). Moreover, currently available scoring systems for assessing the quality of economic analysis 
are, in same cases, not based on a well-known and commonly shared checklist but on key elements 
drawn from different checklists (Chiou 2003; Wallace 2002; Ungar and Santos 2003); others were 
developed which gave a full score to items for which an explicit answer was retrievable in the text 
and half score in the case of a not clear answer in the text (Gonzalez Perez 2002). All these systems 
were judged to be useful for researchers and policy-makers to evaluate the quality of studies, even 
though they have limits. We believe that further effort could be made to assign each item more or 
less weight according to its importance, as noted by Chiu et al. (2003). With this aim, we chose the 
most common and well-known checklist nowadays available to try to develop a new scoring system 
for decision-makers to evaluate the quality of studies and perform stratified and sensitivity analyses 
in systematic reviews. The novelty of the work is the choice of the most commonly used checklist, 
the involvement of experts not necessarily belonging to economists and the attempt to develop a 
user-friendly weighted scoring system.  
The old and new developed checklists were then used to assess the quality of economic analyses on 
tetravalent Human Papillomavirus (HPV) vaccine (against genotypes 6, 11, 16 and 18). This work 
derives from a Health Technology Assessment (HTA) project about the tetravalent HPV vaccine 
(La Torre 2009). HTA is a multidisciplinary approach to evaluate the introduction or the 
implementation of technology that takes into account epidemiological, clinical, technical, economic, 
organisational, social, legal, ethical topics; HPV vaccine was the first which aimed to prevent an 
oncological disease. In carrying out HTA on tetravalent HPV vaccine, published economic analyses 
on tetravalent vaccine were assessed in order to evaluate their quality and to summarise data about 
its cost-effectiveness. 
The specific aims of this work were: 1) to attribute a weight to the items of the original 
Drummond’s checklist which was employed to assess the quality of studies; 2) to apply the original 
and the weighted Drummond’s checklist to the economic analyses of tetravalent HPV vaccine as a 
case study of the application of the weighted checklist. 
 
METHODS 
Checklist weighting process  
The British Medical Journal (BMJ) referees’ checklist, proposed by Drummond et al. (1996) and 
specific for economic evaluation, was chosen as the quality assessment tool for the study. It is 
composed of 35 items divided into 3 sections: study design (7 items), data collection (14 items) and 
analysis and interpretation of results (14 items). Each item could be completely satisfied (Yes) or 
not (No) or not clearly reported (Not clear) or not applicable (Not appropriate). 
To accomplish for our first objective, that to attribute a weight to each item of the checklist, an 
opportunistic sample of experts (Consensus) in health economics, epidemiology and public health 
was selected among key professionals involved in economic evaluation in Italy. The opportunistic 
sample of experts was asked, by e-mail, to attribute, according to their personal knowledge and 
experience, a possible score from 1 to 4 to each item of the original Dummond’s checklist: 
 Score 1: Less important item; 
 Score 2: Important item; 
 Score 3: Very important item; 
 Score 4: Essential item. 
Whenever an answer to the first invitation was not obtained, a maximum of two reminders by email 
were sent. The median values of weights assigned by the Consensus to each item were considered 
to compute the highest global and section scores. 
The Kruskal-Wallis test was applied to assess any difference in weights assigned to each item by 
the three groups of experts involved in weighting. The result of Kruskal-Wallis was used to make 
the decision to combine data from all the experts or to perform a separate analysis according to the 
experts’ backgrounds.  
The statistical significant level was set at p=0.05. The statistical analysis was performed using SPSS 
12.0 for Windows. 
 
Identification of relevant studies and quality assessment 
A bibliographic search of articles written in English on the economic evaluation of HPV tetravalent 
vaccine was performed (until 1
st
 March 2009) using Pubmed. The search was carried out on 
Pubmed using the following algorithm: ("Quadrivalent"[All Fields] OR "tetravalent"[All Fields]) 
AND ("Papillomavirus Vaccines"[All Fields] OR "Papillomavirus Vaccines"[Mesh] OR "HPV 
vaccine"[All Fields]) AND ("Costs and Cost Analysis"[All Fields] OR "Costs and Cost 
Analysis"[Mesh] OR “Cost-Benefit Analysis"[Mesh]). In order to identify other possible studies of 
interest, electronic research was supplemented by manual examination of the reference lists of 
articles found by the Pubmed search, in order to find out all the available full and partial economic 
evaluations of HPV tetravalent vaccine. Economic analyses published only on national reports of 
technology evaluation were not included in our analysis. 
In the selection process, abstracts were first read independently by two researchers (CdW and NN) 
to identify potentially eligible papers whose full text was retrieved and assessed in order to decide 
on the final inclusion. 
For each selected study, two researchers (CdW and NN) assessed independently the quality 
according to the original Drummond’s checklist. Discrepancies between the two investigators were 
solved by oral discussion and consensus with a senior investigator (GLT). After this first 
evaluation, each item was assigned with the median weight attributed by the Consensus, if satisfied 
at the application of the original Drummond’s checklist. Finally the global score was computed 
summing up weights of each item. To compare between studies, global scores were referred, in 
percentage, to the highest score achievable with the weighted Drummond’s checklist. 
 
RESULTS 
Checklist weighting process  
The Consensus of experts selected for the weighting was composed of 25 people; 17 of them agreed 
to partecipate (6 health economists, 5 epidemiologists and 6 public health experts). Non-responders 
were 2 epidemiologists, 2 public health experts and 4 health economists; 3 refused to join the 
Consensus while the others did not answer the mail invitations. The Drummond’s checklist with 
median weights assigned to each item is shown in table 1. In the table, median scores given by each 
group of experts are also reported alongside with p-values resulted by the Kruskal-Wallis test.  
    Please insert table 1 here 
For each section of items the maximum achievable score was as follows: 
1. Study design (7 items): 
Maximum global score = 26; 
2. Data collection (14 items): 
Maximum global score = 45; 
3. Analysis and interpretation of results (14 items): 
a. Maximum global score = 48; 
Little differences were observed between weights assigned by the three expert groups: none of the 
35 items produced a statistically significant difference. 
The global achievable highest score (table 1) was thus 119.  
 
Identification of relevant studies 
From the literature search (35) and bibliographic list reviewed (45), 80 potential eligible studies 
were retrieved. After title and abstracts reading, 21 passed to the full-text review. Thirteen out of 21 
papers were finally included in the analysis (Insinga 2007; Insinga 2008; Chesson 2008; Elbasha 
2007; Brisson 2007; Bergeron 2008; Ginsberg 2007; Boot 2007; Dasbach 2008; Szucs 2008; 
Kulasingam 2008; Jit 2008; Mennini 2005). All the articles which dealt with economic analysis of 
bivalent vaccine (against genotypes 16 and 18) were excluded as well as papers in non English 
language. Details about excluded articles are reported in figure 1. Twelve out of 13 papers were 
cost-effectiveness analyses while one (Insinga 2008) was a cost of illness analysis based on the 
FUTURE study, a trial on HPV tetravalent vaccine.    
Please insert figure 1 here 
 
Quality assessment   
Considering the original Drummond’s checklist, all the studies clearly defined the research 
objective and question (item 1) and sources of efficacy data (item 8), and reported appropriate 
conclusions (item 34) giving a satisfactory answer to the research question (item 33). In most 
studies (about 8-12 out of 13) something was stated about the economic importance of the research 
(item 2), viewpoint of analysis was clarified and justified (item 3), comparators and rationale of 
their choice were clearly described (items 4 and 5). In the mean time, economic analysis type (item 
6), outcomes (item 11), methods to evaluate health status and benefits (item 12), money currency 
(item 18), model details (item 20), time horizon of analysis (item 22) and discount rate (item 23) 
were described. Moreover most studies stated that a sensitivity analysis was performed (item 27) 
and described ranges of parameter variation (item 29). Most studies compared relevant alternatives 
in the model (item 30) and reported incremental analysis (item 31); the studies’ limits were 
moreover discussed in most of works (item 35). 
The flaws identified in the studies were: the choice of the model was not justified (item 7), details 
of efficacy sources and of patients on whom data were retrieved were missing (items 9 and 13); 
resources and costs were not reported separately (16), methods for their computation were not 
described (item 17) and details of adjustment for inflation or currency conversion (item 19) were 
not given. Moreover the choice of model, parameters, discount rate and parameters to vary was not 
justified (items 21, 24, 28). Studies were lacking details of statistical analysis (item 26) and results 
were often reported only in an aggregate way (item 32). For details about each single item see table 
2. 
     Please insert table 2 here 
According to our weighted Drummond’s checklist, the median quality score of selected studies 
resulted 74 (Min: 46; Max: 80). The highest score was reached in the study design section; median 
score of this part was 19 (Min: 12; Max: 26) and only one study (Brisson 2007) attained the 
maximum possible score. Good results were achieved also in the analysis and interpretation of 
results section: median score was 30 (Min: 21; Max: 42). 
The lowest median score was observed in the data collection (Median: 22; Min: 10; Max: 31). Table 
3 shows quality assessment results. It can be noted that almost all studies received a quality score 
over the 50% of the highest possible, 119, but none reached 70% of it. 
     Please insert table 3 here 
 
DISCUSSION  
The present study deals with Drummond’s checklist which is already widely used by authors and 
reviewers to assess the completeness of economic analysis reporting. Different attempts to assess 
the quality of reporting have been carried out by different authors.   
Neumann et al. (2000) published a work about the assessment of 228 cost-utility analyses over the 
period 1976-97; they employed a form, developed on the basis of the “checklist” for reporting 
reference-case cost-utility analyses recommended by the Panel on Cost-Effectiveness in Health and 
Medicine (Siegel 1996), other published guidelines and by recommendations and discussions with 
experts in the field. Collected data ranged from disclosure of funding sources, reporting of the 
framing of analysis, reporting of costs, preference weights, results, and description of key elements 
in the discussion section. The results revealed that the weakest parts were the definition of study 
perspective, the provision of a diagram of the model or event pathway, the reporting of the discount 
rate for both costs and quality adjusted life years, the definition of the year in which monetary units 
were valued, the appropriate reporting of incremental cost-effectiveness ratios and the discussion of 
ethical implications.  
Further experiences on evaluation of economic analyses were carried out in the 1990s. Gerard et al. 
(1999) showed incongruent
 
perspectives and serious deficiencies in the estimation of costs,
 
interpretation of results and the use of patients for eliciting
 
utility weights, whereas Petrou et al. 
(2000) analysed 41 works on antenatal screenings accounting for methodological topics on the basis 
of Drummond’s guideline. The weakest areas were: failure to provide detailed and disaggregated 
information on reported costs, failure to discount future care costs and the poor use of sensitivity 
analysis, often applied only to clinical or epidemiological parameters. 
Our study adds the weighting of each evaluation item to previous analyses. The assessing of the 
quality of economic analyses aids informed reading of the current literature and improves 
homogeneity and reliability of decision-making process. That is why we chose to use a newly 
developed and widely used checklist to weight the importance of each item using the opinions of a 
group of well-known experts in epidemiology, public health and economics who were involved in 
health economic analyses from different viewpoints and thus representative of all the perspectives 
in the evaluation of economic analysis. The development of the weighting system was the main goal 
of our work so that assessment of the quality of economic analyses could be more thorough. It must 
be underlined that other attempts to weight Drummond’s checklist have been reported: Gonzalez-
Perez (2002) demonstrated that the development of a weighting system improves discrimination of 
the quality of studies and of their importance, robustness and correctness. 
The present work of weighting found that the most important aspects to be considered in economic 
analyses are: for study design, the definition/justification of the research question, viewpoint of 
analysis, alternatives and form of economic evaluation; for data collection, the description of 
outcomes, model and its parameters, sources of effectiveness data and methods to evaluate health 
benefits and costs; for interpretation of results, the identification of the time horizon, discount rate 
and sensitivity analysis and justification of conclusions. 
Most of these elements were identified as main flaws of economic analyses by Drummond
 
(2005) 
himself; he also underlined the potential problems coming from indirect comparisons, inappropriate 
extrapolation beyond the period observed in clinical studies, the excessive use of assumptions rather 
than data, and the selective reporting of findings.  
The well recognised importance of such elements could justify, in our opinion, the development of 
a scoring system able to assign different value to single items of already available checklists. 
Also it is very interesting to observe that methodological lacks and flaws are not only present in 
published studies but also in economic evaluations of dossiers sent to institutional bodies for 
decisions on drugs reimbursement or price. This was verified both in Italy and in an international 
setting (Russo 2008; Hill 2000). For these reasons, in our opinion, it is important to underline that 
the introduction of a new technology, such as a vaccine, should be based not only on economic 
evaluation but on a multidisciplinary assessment, such as the Health Technology Assessment which 
also includes an economic evaluation (La Torre 2007). 
Our second aim was to apply the Drummond’s tool, both as checklist and as quality score system, to 
the economic evaluations of HPV tetravalent vaccine in the context of an HTA project.  HPV 
vaccine is a relatively new topic in the international scenario and in Italy has been introduced, free 
of charge, for twelve years old girls; the increasing interest has led during the last two years to 
several publications concerning health economic aspects. It is presumable that the growing interest 
in economic assessment has been also driven by the need for evidence to support decision-makers. 
Our review yielded 13 papers on the economic evaluation of HPV tetravalent vaccine: 4 of them 
were American (2 in USA, 1 in Canada, 1 in Mexico) whereas 7 were European and 1 Israeli. One 
study was the economic evaluation of the FUTURE II study, a multicentric randomised clinical trial 
on tetravalent vaccine.  
After assessing the articles for quality, economic evaluations of HPV tetravalent vaccine were 
found to be of medium quality. The most important quality problems were in “data collection” and 
“analysis and interpretation of results”. For data collection, lack of quality was mainly due to 
problems about reporting of efficacy, utility, resources and costs sources. On the other hand, 
analysis and interpretation of results were affected by lack of statistical details, justification of 
discount rates and sensitivity analysis. It is interesting to observe that these items were assigned the 
highest weights by the Consensus: this means that the quality evaluation performed with the 
weighted Drummond’s checklist led to relative worse results than the application of the original un-
weighted checklist. 
Our work does have limitations. First, one of the most important weaknesses is that the weighting 
of Drummond’s checklist items was performed only by a narrow group of experts who were all 
Italians. This means that our work is not conclusive and further experience of weight attribution 
nationally and internationally would be desirable; the validation of the system of weights assigned 
by the Consensus of experts should be monitored in order to assess its reliability. Moreover, the 
scoring system used here cannot reflect the total quality of papers because Drummond’s checklist is 
focused on reporting of results and not on methods used to carry out the analysis. In any case, it 
may be difficult to standardise some aspects of economic evaluations such as the kind of model to 
use or the discount rate to apply.  For this review of HPV tetravalent vaccine economic analyses, 
the main weakness is the possible selection bias due to the search strategy; in fact, a lot of studies 
have been carried out worldwide to investigate the economic implications of this vaccine, and thus 
it is possible that several studies were not selected. The limited search strategy excluded economic 
analyses reported only on HTA dossiers and not published in peer review journals available on 
Pubmed. Moreover, studies carried out in Asia or in Africa, as well as in other countries but not 
written in English, could not be included in the analysis. Alongside selection bias, sponsor bias and 
publication bias cannot be excluded.  
CONCLUSION 
Drummond’s checklist could be proposed as a standard reference to evaluate economic analyses 
and the system of weights could lead to better quality assessment. This could improve a critical 
evaluation of literature.  
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Table 1: Drummond’s checklist weighting – median score for each item by different experts 
 
  ITEM 
G
lo
b
a
l 
w
ei
g
h
t 
H
ea
lt
h
 
E
co
n
o
m
is
ts
 
P
u
b
li
c 
h
ea
th
 
ex
p
er
ts
 
E
p
id
e
m
io
lo
g
is
ts
 
p
-v
a
lu
e*
 
S
T
U
D
Y
 D
E
S
IG
N
 1 The research question is stated 4 4 4 4 0.99 
2 The economic importance of the research question is stated 3 3 3.5 3 0.56 
3 The viewpoints of the analysis are clearly stated and justified 4 4 4 3 0.09 
4 The rationale for choosing the alternatives programs or interventions compared   is stated 4 4 4 3 0.71 
5 The alternatives being compared are clearly described 4 4 3.5 3 0.10 
6 The form of economic evaluation used is stated 4 3.5 4 4 0.46 
7 The choice of form of economic evaluation is justified in relation to the question addressed 3 3 3 3 0.59 
 Total 26 25.5 26 23 
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8 The sources of effectiveness estimates used are stated 4 4 4 4 0.40 
9 
The details of the design and results of effectiveness study are given (if based on a single 
study) 
3 3.5 3 4 0.55 
10 
Details of the method of synthesis or meta-analysis of estimates are given (if based on an 
overview of a number of effectiveness study) 
3 3.5 3 4 0.50 
11 The primary outcome measures for the economic evaluation are clearly stated 4 4 4 4 0.79 
12 Methods to value health states and other benefits are stated 4 4 3.5 4 0.41 
13 Details of the subjects from whom evaluations were obtained are given 3 2.5 3 3 0.42 
14 Productivity changes (if included) are reported separately 2 2.5 2.5 2 0.33 
15 The relevance of productivity changes to the study question is discussed 2 2 3 2 0.57 
16 Quantities of resources are reported separately from their unit costs 3 3 3 3 0.73 
17 Methods for the estimation of quantities and unit costs are described 4 4 3 4 0.40 
18 Currency and price data are recorded 3 4 3 3 0.15 
19 Details of currency of price adjustment for inflation or currency conversion are given 3 2.5 2.5 3 0.82 
20 Details of any model used are given 3 3.5 3 4 0.07 
21 The choice of model used and the key parameters on which it is based are justified 4 3.5 3 4 0.08 
 Total 45 46.5 43.5 48  
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22 Time horizon of costs and benefits is stated 4 4 4 4 0.95 
23 The discount rate is stated 4 4 3 4 0.78 
24 The choice of rates are justified 3 3.5 3 3 0.66 
25 An explanation is given if costs or benefits are not discounted 3 2.5 3 3 0.46 
26 Details of statistical tests and confidence intervals are given for stochastic data 3 3 3 4 0.78 
27 The approach to sensitivity analysis is given 4 3.5 4 3 0.42 
28 The choice of variables for sensitivity analysis is justified 3 3 3 3 0.62 
29 The ranges over which the variables are varied are stated 3 3.5 3 3 0.22 
30 Relevant alternatives are compared 3 4 3 3 0.06 
31 Incremental analysis is reported 3 4 3 2 0.09 
32 Major outcomes are presented in a disaggregated as well as aggregated form 3 2.5 3.5 3 0.61 
33 The answer to the study question is given 4 4 4 4 0.97 
34 Conclusions follow from the data reported  4 4 4 4 0.14 
35 Conclusions are accompanied by the appropriate caveats 4 3.5 3.5 4 0.17 
Total 48 49 47 47  
*
 Kruskal-Wallis applied to investigate differences between the three groups of experts                   Total 119 121 116.5 118  
 
Table 2: Quality assessment results, according to Drummond’s checklist 
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1 The research question is stated 13 0 0 0 
2 The economic importance of the research question is stated 10 3 0 0 
3 The viewpoints of the analysis are clearly stated and justified 9 3 1 0 
4 
The rationale for choosing the alternatives programs or interventions compared   is 
stated 
8 4 0 1 
5 The alternatives being compared are clearly described 11 1 1 0 
6 The form of economic evaluation used is stated 12 0 1 0 
7 
The choice of form of economic evaluation is justified in relation to the question 
addressed 
3 9 0 1 
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8 The sources of effectiveness estimates used are stated 13 0 0 0 
9 
The details of the design and results of effectiveness study are given (if based on a 
single study) 
3 7 1 2 
10 
Details of the method of synthesis or meta-analysis of estimates are given (if based 
on an overview of a number of effectiveness study) 
0 3 0 9 
11 The primary outcome measures for the economic evaluation are clearly stated 11 0 2 0 
12 Methods to value health states and other benefits are stated 11 1 1 0 
13 Details of the subjects from whom evaluations were obtained are given 6 6 1 0 
14 Productivity changes (if included) are reported separately 1 0 0 12 
15 The relevance of productivity changes to the study question is discussed 0 1 0 12 
16 Quantities of resources are reported separately from their unit costs 2 11 0 0 
17 Methods for the estimation of quantities and unit costs are described 4 5 4 0 
18 Currency and price data are recorded 10 3 0 0 
19 Details of currency of price adjustment for inflation or currency conversion are 
given 
5 7 1 0 
20 Details of any model used are given 11 2 0 0 
21 The choice of model used and the key parameters on which it is based are justified 4 7 2 0 
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22 Time horizon of costs and benefits is stated 11 2 0 0 
23 The discount rate is stated 12 0 1 0 
24 The choice of rates are justified 3 9 1 0 
25 An explanation is given if costs or benefits are not discounted 1 2 1 9 
26 Details of statistical tests and confidence intervals are given for stochastic data 0 13 0 0 
27 The approach to sensitivity analysis is given 12 1 0 0 
28 The choice of variables for sensitivity analysis is justified 4 8 0 1 
29 The ranges over which the variables are varied are stated 8 3 1 1 
30 Relevant alternatives are compared 9 4 0 0 
31 Incremental analysis is reported 10 3 0 0 
32 Major outcomes are presented in a disaggregated as well as aggregated form 1 12 0 0 
33 The answer to the study question is given 13 0 0 0 
34 Conclusions follow from the data reported  13 0 0 0 
35 Conclusions are accompanied by the appropriate caveats 12 1 0 0 
 
 
Table 3. Results of quality assessment with weighted Drummond’s checklist 
 
  
STUDY 
DESIGN 
DATA 
COLLECTION 
ANALYSIS AND 
INTERPRETATION OF RESULTS 
FINAL 
SCORE 
TOTAL RELATIVE 
SCORE^ 
Bergeron 2008 15 21 42 78 65.5 
Boot 2007 15 10 21 46 38.7 
Brisson 2007 26 17 26 69 58.0 
Chesson 2008 22 25 29 76 63.9 
Dasbach 2008 19 31 30 80 67.2 
Elbasha 2007 19 14 33 66 55.5 
Ginsberg 2007 23 24 33 80 67.2 
Insinga 2007 23 21 30 74 62.2 
Insinga 2008 12 28 30 70 58.8 
Jit 2008 19 21 30 70 58.8 
Kulasingam 2008 16 26 30 72 60.5 
Mennini 2009 23 22 33 78 65.5 
Szucs 2008 19 25 33 77 64.7 
^ The total relative score was computed dividing the final score by the maximum achievable score of 119. 
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Figure 1. Flow-chart of the selection process 
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